Stealth nanoparticles coated with heparin as peptide or protein carriers

References

• Ardy M. (1976). Dosage de l’héparine: étude cinétique. Bull Ordre, 137, 699–707.
   Google Scholar
• Awasthi VD, Garcia D, Goins BA, Phillips WT. (2003). Circulation and biodistribution profiles of long-circulating PEG-liposomes of various sizes in rabbits. Int J Pharm, 253, 121–132.
   PubMed Web of Science ®Google Scholar
• Bazile D, Prud’homme C, Bassoullet MT, Marlard M, Spenlehauer G, Veillard M. (1995). Stealth Me.PEG-PLA nanoparticles avoid uptake by the mononuclear phagocytes system. J Pharm Sci, 84, 493–498.
   PubMed Web of Science ®Google Scholar
• Béduneau A, Saulnier P, Anton N, Hindré F, Passirani C, Rajerison H, Noiret N, Benoit J-P. (2006). Pegylated nanocapsules produced by an organic solvent-free method: evaluation of their stealth properties. Pharm Res, 23, 2190–2199.
   PubMed Web of Science ®Google Scholar
• Bocca C, Caputo O, Cavalli R, Gabriel L, Miglietta A, Gasco MR. (1998). Phagocytic uptake of fluorescent stealth and non-stealth solid lipid nanoparticles. Int J Pharm, 175, 185–193.
   Web of Science ®Google Scholar
• Charrois GJ, Allen TM. (2003). Multiple injections of pegylated liposomal Doxorubicin: pharmacokinetics and therapeutic activity. J Pharmacol Exp Ther, 306, 1058–1067.
   PubMed Web of Science ®Google Scholar
• Chernysheva YV, Babak VG, Kildeeva NR, Boury F, Benoit JP, Ubrich N, Maincent P. (2003). Effect of the type of hydrophobic polymers on the size of nanoparticles obtained by emulsification-solvent evaporation. Mendeleev Commun, 13, 65–67.
   Web of Science ®Google Scholar
• Damgé C, Maincent P, Ubrich N. (2007). Oral delivery of insulin associated to polymeric nanoparticles in diabetic rats. J Control Release, 117, 163–170.
   PubMed Web of Science ®Google Scholar
• Damgé C, Michel C, Aprahamian M, Couvreur P. (1988). New approach for oral administration of insulin with polyalkylcyanoacrylate nanocapsules as drug carrier. Diabetes, 37, 246–251.
   PubMed Web of Science ®Google Scholar
• Ekre HP, Naparstek Y, Lider O, Hyden P, Hagermark O, Nilsson T, Vlodavsky I, Cohen I. (1992). Anti-inflammatory effects of heparin and its derivatives: inhibition of complement and of lymphocyte migration. Adv Exp Med Biol, 313, 329–340.
   PubMedGoogle Scholar
• Fang C, Shi B, Pei YY. (2005). Effect of MePEG molecular weight and particle size on in vitro release of tumor necrosis factor-alpha-loaded nanoparticles. Acta Pharmacol Sin, 26, 242–249.
   PubMed Web of Science ®Google Scholar
• Fang C, Shi B, Pei YY, Hong MH, Wu J, Chen HZ. (2006). In vivo tumor targeting of tumor necrosis factor-alpha-loaded stealth nanoparticles: effect of MePEG molecular weight and particle size. Eur J Pharm Sci, 27, 27–36.
   PubMed Web of Science ®Google Scholar
• Fontana G, Licciardi M, Mansueto S, Schillaci D, Giammona G. (2001). Amoxicillin-loaded polyethylcyanoacrylate nanoparticles: influence of PEG coating on the particle size, drug release rate and phagocytic uptake. Biomaterials, 22, 2857–2865.
   PubMed Web of Science ®Google Scholar
• Fundaro A, Cavalli R, Bargoni A, Vighetto D, Zara GP, Gasco MR. (2000). Non-stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: pharmacokinetics and tissue distribution after i.v. administration to rats. Pharmacol Res, 42, 337–343.
   PubMed Web of Science ®Google Scholar
• Furtado S, Abramson D, Simhkay L, Wobbekind D, Mathiowitz E. (2006). Subcutaneous delivery of insulin loaded poly(fumaric-co-sebacic anhydride) microspheres to type 1 diabetic rats. Eur J Pharm Biopharm, 63, 229–236.
   PubMed Web of Science ®Google Scholar
• Gan Q, Wang T. (2007). Chitosan nanoparticle as protein delivery carrier—systematic examination of fabrication conditions for efficient loading and release. Colloids Surf B Biointerfaces, 59, 24–34.
   PubMed Web of Science ®Google Scholar
• Gaur U, Sahoo SK, De TK, Ghosh PC, Maitra A, Ghosh PK. (2000). Biodistribution of fluoresceinated dextran using novel nanoparticles evading reticuloendothelial system. Int J Pharm, 202, 1–10.
   PubMed Web of Science ®Google Scholar
• Gbadamosi JK, Hunter AC, Moghimi SM. (2002). PEGylation of microspheres generates a heterogeneous population of particles with differential surface characteristics and biological performance. FEBS Lett, 532, 338–344.
   PubMed Web of Science ®Google Scholar
• Gref R, Luck M, Quellec P, Marchand M, Dellacherie E, Harnisch S, Blunk T, Muller RH. (2000). “Stealth” corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surf B Biointerfaces, 18, 301–313.
   PubMed Web of Science ®Google Scholar
• Gregoriadis G, Leathwood PD, Ryman BE. (1971). Enzyme entrapment in liposomes. FEBS Lett, 14, 95–99.
   PubMed Web of Science ®Google Scholar
• Hockertz S, Franke G, Kniep E, Lohmann-Matthes ML. (1989). Mouse interferon-gamma in liposomes: pharmacokinetics, organ-distribution, and activation of spleen and liver macrophages in vivo. J Interferon Res, 9, 591–602.
   PubMedGoogle Scholar
• Hoffart V, Ubrich N, Lamprecht A, Bachelier K, Vigneron C, Lecompte T, Hoffman M, Maincent P. (2003). Microencapsulation of low molecular weight heparin into polymeric particles designed with biodegradable and nonbiodegradable polycationic polymers. Drug Deliv, 10, 1–7.
   PubMed Web of Science ®Google Scholar
• Hsu MJ, Juliano RL. (1982). Interactions of liposomes with the reticuloendothelial system. II: Nonspecific and receptor-mediated uptake of liposomes by mouse peritoneal macrophages. Biochim Biophys Acta, 720, 411–419.
   PubMed Web of Science ®Google Scholar
• Huang M, Wu W, Qian J, Wan DJ, Wei XL, Zhu JH. (2005). Body distribution and in situ evading of phagocytic uptake by macrophages of long-circulating poly (ethylene glycol) cyanoacrylate-co-n-hexadecyl cyanoacrylate nanoparticles. Acta Pharmacol Sin, 26, 1512–1518.
   PubMed Web of Science ®Google Scholar
• Jameela SR, Suma N, Jayakrishnan A. (1997). Protein release from poly(epsilon-caprolactone) microspheres prepared by melt encapsulation and solvent evaporation techniques: a comparative study. J Biomater Sci Polym Ed, 8, 457–466.
   PubMed Web of Science ®Google Scholar
• Jaulin N, Appel M, Passirani C, Barratt G, Labarre D. (2000). Reduction of the uptake by a macrophagic cell line of nanoparticles bearing heparin or dextran covalently bound to poly(methyl methacrylate). J Drug Target, 8, 165–172.
   PubMed Web of Science ®Google Scholar
• Jiao YY, Ubrich N, Hoffart V, Marchand-Arvier M, Vigneron C, Hoffman M, Maincent P. (2002). Preparation and characterization of heparin-loaded polymeric microparticles. Drug Dev Ind Pharm, 28, 1033–1041.
   PubMed Web of Science ®Google Scholar
• Kazatchkine MD, Fearon DT, Silbert JE, Austen KF. (1979). Surface-associated heparin inhibits zymosan-induced activation of the human alternative complement pathway by augmenting the regulatory action of the control proteins on particle-bound C3b. J Exp Med, 150, 1202–1215.
   PubMed Web of Science ®Google Scholar
• Kazatchkine MD, Hauptmann G, Nydegger UE. (1986). Techniques du complément. Paris: Inserm.
   Google Scholar
• Kedar E, Gur H, Babai I, Samira S, Even-Chen S, Barenholz Y. (2000). Delivery of cytokines by liposomes: hematopoietic and immunomodulatory activity of interleukin-2 encapsulated in conventional liposomes and in long-circulating liposomes. J Immunother, 23, 131–145.
   PubMed Web of Science ®Google Scholar
• Labarre D, Vauthier C, Chauvierre C, Petri B, Muller R, Chehimi MM. (2005). Interactions of blood proteins with poly(isobutylcyanoacrylate) nanoparticles decorated with a polysaccharidic brush. Biomaterials, 26, 5075–5084.
   PubMed Web of Science ®Google Scholar
• Labarre DJ. (1990). Heparin-like polymer surfaces: control of coagulation and complement activation by insoluble functionalized polymers. Int J Artif Organs, 13, 651–657.
   PubMed Web of Science ®Google Scholar
• Lappegard KT, Fung M, Bergseth G, Riesenfeld J, Lambris JD, Videm V, Mollnes TE. (2004). Effect of complement inhibition and heparin coating on artificial surface-induced leukocyte and platelet activation. Ann Thorac Surg, 77, 932–941.
   PubMed Web of Science ®Google Scholar
• Lemarchand C, Gref R, Passirani C, Garcion E, Petri B, Muller R, Costantini D, Couvreur P. (2006). Influence of polysaccharide coating on the interactions of nanoparticles with biological systems. Biomaterials, 27, 108–118.
   PubMed Web of Science ®Google Scholar
• Levchenko TS, Rammohan R, Lukyanov AN, Whiteman KR, Torchilin VP. (2002). Liposome clearance in mice: the effect of a separate and combined presence of surface charge and polymer coating. Int J Pharm. 240, 95–102.
   PubMed Web of Science ®Google Scholar
• Li Y, Pei Y, Zhang X, Gu Z, Zhou Z, Yuan W, Zhou J, Zhu J, Gao X. (2001). PEGylated PLGA nanoparticles as protein carriers: synthesis, preparation and biodistribution in rats. J Control Release, 71, 203–211.
   PubMed Web of Science ®Google Scholar
• Liu W, Yang A, Li Z, Xu H, Yang X. (2007). PEGylated PLGA nanoparticles as tumor necrosis factor-α receptor blocking peptide carriers: Preparation, characterization and release in vitro. J Wuhan Univ Technol—Mater Sci Ed, 22, 112–116.
   Web of Science ®Google Scholar
• Maillet F, Kazatchkine MD, Glotz D, Fischer E, Rowe M. (1983). Heparin prevents formation of the human C3 amplification convertase by inhibiting the binding site for B on C3b. Mol Immunol, 20, 1401–1404.
   PubMed Web of Science ®Google Scholar
• Marchal-Heussler L, Thouvenot P, Hoffman M, Maincent P. (1999). Comparison of the biodistribution in mice of 111 indium oxine encapsulated into poly(lactic-co-glycolic)-D,L-85/15 and poly(epsilon caprolactone) nanocapsules. J Pharm Sci, 88, 450–453.
   PubMed Web of Science ®Google Scholar
• Mayer MM. (1961). Experimental Immunochemistry. Springfield, IL: Thomas.
   Google Scholar
• Moghimi SM, Hunter AC, Murray JC. (2001). Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev, 53, 283–318.
   PubMed Web of Science ®Google Scholar
• Moghimi SM, Pavey KD, Hunter AC. (2003). Real-time evidence of surface modification at polystyrene lattices by poloxamine 908 in the presence of serum: in vivo conversion of macrophage-prone nanoparticles to stealth entities by poloxamine 908. FEBS Lett, 547, 177–182.
   PubMed Web of Science ®Google Scholar
• Moslemi P, Najafabadi AR, Tajerzadeh H. (2003). A rapid and sensitive method for simultaneous determination of insulin and A21-desamido insulin by high-performance liquid chromatography. J Pharm Biomed Anal, 33, 45–51.
   PubMed Web of Science ®Google Scholar
• Muller RH, Maassen S, Schwarz C, Mehnert W. (1997). Solid lipid nanoparticles (SLN) as potential carrier for human use: interaction with human granulocytes. J Control Release, 47, 261–269.
   Web of Science ®Google Scholar
• Okuda T, Kawakami S, Maeie T, Niidome T, Yamashita F, Hashida M. (2006). Biodistribution characteristics of amino acid dendrimers and their PEGylated derivatives after intravenous administration. J Control Release, 114, 69–77.
   PubMed Web of Science ®Google Scholar
• Oppenheim RC. (1981). Solid colloidal drug delivery systems: Nanoparticles. Int J Pharm, 8, 217–234.
   Web of Science ®Google Scholar
• Passirani C, Barratt G, Devissaguet JP, Labarre D. (1998). Interactions of nanoparticles bearing heparin or dextran covalently bound to poly(methyl methacrylate) with the complement system. Life Sci, 62, 775–785.
   PubMed Web of Science ®Google Scholar
• Passirani C, Barratt G, Devissaguet JP, Labarre D. (1998). Long-circulating nanoparticles bearing heparin or dextran covalently bound to poly(methyl methacrylate). Pharm Res, 15, 1046–1050.
   PubMed Web of Science ®Google Scholar
• Quellec P, Gref R, Dellacherie E, Sommer F, Tran MD, Alonso MJ. (1999). Protein encapsulation within poly(ethylene glycol)-coated nanospheres. II. Controlled release properties. J Biomed Mater Res, 47, 388–395.
   PubMed Web of Science ®Google Scholar
• Quellec P, Gref R, Perrin L, Dellacherie E, Sommer F, Verbavatz JM, Alonso MJ. (1998). Protein encapsulation within polyethylene glycol-coated nanospheres. I. Physicochemical characterization. J Biomed Mater Res, 42, 45–54.
   PubMed Web of Science ®Google Scholar
• Reddy LH, Sharma RK, Chuttani K, Mishra AK, Murthy RR. (2004). Etoposide-incorporated tripalmitin nanoparticles with different surface charge: formulation, characterization, radiolabeling, and biodistribution studies. Aaps J, 6, e23.
   PubMed Web of Science ®Google Scholar
• Roser M, Fischer D, Kissel T. (1998). Surface-modified biodegradable albumin nano- and microspheres. II: effect of surface charges on in vitro phagocytosis and biodistribution in rats. Eur J Pharm Biopharm, 46, 255–263.
   PubMed Web of Science ®Google Scholar
• Sengupta S, Tyagi P, Velpandian T, Gupta YK, Gupta SK. (2000). Etoposide encapsulated in positively charged liposomes: pharmacokinetic studies in mice and formulation stability studies. Pharmacol Res, 42, 459–464.
   PubMed Web of Science ®Google Scholar
• Socha M, Lamprecht A, El Ghazouani F, Emond E, Maincent P, Barré J, Hoffman M, Ubrich N. (2008). Increase in the vascular residence time of propranolol-loaded nanoparticles coated with heparin. J Nanosci Nanotechnol, 8, 2369–2376.
   PubMed Web of Science ®Google Scholar
• Tobio M, Gref R, Sanchez A, Langer R, Alonso MJ. (1998). Stealth PLA-PEG nanoparticles as protein carriers for nasal administration. Pharm Res, 15, 270–275.
   PubMed Web of Science ®Google Scholar
• Verrecchia T, Spenlehauer G, Bazile DV, Murry-Brelier A, Archimbaud Y, Veillard M. (1995). Non-stealth (poly(lactic acid/albumin)) and stealth (poly(lactic acid-polyethylene glycol)) nanoparticles as injectable drug carriers. J Control Release, 36, 49–61.
   Web of Science ®Google Scholar
• Vittaz M, Bazile D, Spenlehauer G, Verrecchia T, Veillard M, Puisieux F, Labarre D. (1996). Effect of PEO surface density on long-circulating PLA-PEO nanoparticles which are very low complement activators. Biomaterials, 17, 1575–1581.
   PubMed Web of Science ®Google Scholar
• Vonarbourg A, Passirani C, Saulnier P, Simard P, Leroux JC, Benoit JP. (2006). Evaluation of pegylated lipid nanocapsules versus complement system activation and macrophage uptake. J Biomed Mater Res A, 78, 620–628.
   PubMed Web of Science ®Google Scholar
• Xu X, Fu Y, Hu H, Duan Y, Zhang Z. (2006). Quantitative determination of insulin entrapment efficiency in triblock copolymeric nanoparticles by high-performance liquid chromatography. J Pharm Biomed Anal, 41, 266–273.
   PubMed Web of Science ®Google Scholar
• Yang A, Yang L, Liu W, Li Z, Xu H, Yang X. (2007). Tumor necrosis factor alpha blocking peptide loaded PEG-PLGA nanoparticles: preparation and in vitro evaluation. Int J Pharm, 331, 123–132.
   PubMed Web of Science ®Google Scholar
• Zambaux MF, Bonneaux F, Gref R, Dellacherie E, Vigneron C. (1999). Preparation and characterization of protein C-loaded PLA nanoparticles. J Control Release, 60, 179–188.
   PubMed Web of Science ®Google Scholar